The Goldman Sachs Group upgraded shares of Revolution Medicines (NASDAQ:RVMD – Free Report) to a strong-buy rating in a report issued on Thursday morning,Zacks reports. Other analysts have also recently issued research reports about the stock. Royal Bank Of Canada raised their price objective on shares of Revolution Medicines from $203.00 to $251.00 and gave […]

The Goldman Sachs Group upgraded shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) to a strong-buy rating in a report published on Thursday,Zacks reports. IOVA has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Barclays […]

The Goldman Sachs Group upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) to a hold rating in a research report released on Thursday,Zacks reports. A number of other analysts have also commented on ALKS. JPMorgan Chase & Co. boosted their target price on Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating […]

Bruker (NASDAQ:BRKR – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group from a “strong sell” rating to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports. Several other research analysts have also recently weighed in on the stock. Leerink Partners boosted their price target on […]

Abivax (NASDAQ:ABVX – Get Free Report) was upgraded by equities research analysts at The Goldman Sachs Group to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports. Several other equities analysts have also issued reports on the stock. Guggenheim reiterated a “buy” rating on shares of Abivax in a report on […]